BR112012018122A2 - "método e usos relacionados à identificação de coposto envolvido na dor, bem como métodos para diagnosticar algesia" - Google Patents

"método e usos relacionados à identificação de coposto envolvido na dor, bem como métodos para diagnosticar algesia"

Info

Publication number
BR112012018122A2
BR112012018122A2 BR112012018122A BR112012018122A BR112012018122A2 BR 112012018122 A2 BR112012018122 A2 BR 112012018122A2 BR 112012018122 A BR112012018122 A BR 112012018122A BR 112012018122 A BR112012018122 A BR 112012018122A BR 112012018122 A2 BR112012018122 A2 BR 112012018122A2
Authority
BR
Brazil
Prior art keywords
pain
methods
well
diagnosing
identification
Prior art date
Application number
BR112012018122A
Other languages
English (en)
Inventor
Mathias Gebauer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012018122A2 publication Critical patent/BR112012018122A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

patente de invenção: "método e usos relacionados à identificação de composto envolvido na dor, bem como métodos para diagnosticar algesia". a presente invenção refere-se a um método para identificar um composto envolvido na dor, o uso de ácido nucleico car 3 ou proteína car 3 para identificar um composto envolvido na dor bem como métodos para diagnosticar agelsia envolvendo os mesmos.
BR112012018122A 2010-01-21 2011-01-20 "método e usos relacionados à identificação de coposto envolvido na dor, bem como métodos para diagnosticar algesia" BR112012018122A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305067A EP2348128A1 (en) 2010-01-21 2010-01-21 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
PCT/EP2011/050771 WO2012052189A1 (en) 2010-01-21 2011-01-20 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

Publications (1)

Publication Number Publication Date
BR112012018122A2 true BR112012018122A2 (pt) 2017-01-10

Family

ID=42112157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018122A BR112012018122A2 (pt) 2010-01-21 2011-01-20 "método e usos relacionados à identificação de coposto envolvido na dor, bem como métodos para diagnosticar algesia"

Country Status (12)

Country Link
US (1) US20130157880A1 (pt)
EP (2) EP2348128A1 (pt)
JP (1) JP2013531968A (pt)
KR (1) KR20120127464A (pt)
CN (1) CN102803513A (pt)
AU (1) AU2011317791A1 (pt)
BR (1) BR112012018122A2 (pt)
CA (1) CA2787463A1 (pt)
MX (1) MX2012008537A (pt)
RU (1) RU2012135677A (pt)
SG (1) SG182653A1 (pt)
WO (1) WO2012052189A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989L (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
GB2377940A (en) * 2001-07-27 2003-01-29 Warner Lambert Co Identification and use of molecules implicated in pain
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20040044181A1 (en) * 2001-08-31 2004-03-04 Tang Y. Tom Novel nucleic acids and polypeptides
EP1336661A1 (en) * 2002-02-14 2003-08-20 Biofrontera Pharmaceuticals AG Multiple genes relevant for the characterisation, diagnosis, and manipulation of neuropatic pain
US20030216341A1 (en) * 2002-02-14 2003-11-20 Hermann Lubbert Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005043973A2 (en) * 2003-10-28 2005-05-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with sk2 channels
US20060084066A1 (en) * 2004-02-20 2006-04-20 Sah Dinah W Y Surrogate markers of neuropathic pain
EP2749571A3 (en) * 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists

Also Published As

Publication number Publication date
EP2348128A1 (en) 2011-07-27
AU2011317791A8 (en) 2013-11-28
CA2787463A1 (en) 2012-04-26
WO2012052189A8 (en) 2012-08-16
WO2012052189A1 (en) 2012-04-26
EP2526203A1 (en) 2012-11-28
KR20120127464A (ko) 2012-11-21
AU2011317791A1 (en) 2012-08-09
CN102803513A (zh) 2012-11-28
SG182653A1 (en) 2012-08-30
RU2012135677A (ru) 2014-02-27
US20130157880A1 (en) 2013-06-20
JP2013531968A (ja) 2013-08-15
MX2012008537A (es) 2012-10-15

Similar Documents

Publication Publication Date Title
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
IL261313B (en) Methods of identification and diagnosis of lung disease using classification systems and kits thereof
AR092818A1 (es) Anticuerpo tau humanizado
BRPI0719879A8 (pt) sal de adição de ácido, processo para sua preparação e seu uso, bem como intermediário químico
BR112015014751A2 (pt) anticorpos anti-tau humanos
BR112013014238A2 (pt) processo para tratar uma formação subterrânea, fluido adequado para uso no processo e sal de amônio da fórmula mx(nh4)yhz-glda ou da fórmula mx(nh4)yhz-mgda
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112012008173A2 (pt) molécula de ligação específica de rsv
BR112014033116A2 (pt) anticorpos para tau
IT1391619B1 (it) Metodo per l'individuazione, selezione e analisi di cellule tumorali
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
BR112015021681A2 (pt) proteínas de ligação para pcsk9
BR112015001327A2 (pt) complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
HK1198591A1 (en) Oxmif as a diagnostic marker
CL2015000709A1 (es) Polipéptido de unión il-17a glicosilada; construcción de fusión; molécula de ácido nucleico que codifica al polipéptido; composición de diagnóstico o farmacéutica para tratar enfermedad inflamatoria, autoinmune y/o relacionada a la pérdida ósea.
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]